ICLR ICON Plc

ICON Secures Upgraded Credit Rating from Moody’s Investors Service

(NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook. This reflects the stronger credit profile of the ICON Group, which Moody’s now views as comparable in aggregate to Baa3 peers. The Baa3 rating of all the instruments reflects Moody’s view that the ICON Group has reached an investment grade financial profile.

Moody’s highlighted in their report that the upgrade of the debt instruments reflects “Moody’s expectation of ICON’s continued good operating performance and conservative financial strategy and risk management policies, a governance consideration under Moody’s ESG framework, and key to the rating action”.

Brendan Brennan, ICON’s Chief Financial Officer, commented: “We are proud of the investment grade rating upgrade from Moody’s, which goes alongside our recent upgrade from S&P and is aligned with our stated long-term capital allocation priorities for ICON. These upgrades and the strong financial position of the company should enable a re-structuring of our overall debt allowing us to significantly reduce our interest cost going forward.”

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 106 locations in 53 countries as at September 30, 2023. For further information about ICON, visit: .

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at .

ICON/ICLR-F

EN
07/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICON Plc

 PRESS RELEASE

ICON plc to hold Investor Day Meeting on May 30, 2024

DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will hold an Investor Day which will take place on Thursday, May 30, 2024 in New York City, starting at 10am ET. The event will include presentations from members of ICON’s executive team, and access to a live webcast will be made available in on the Investor section of our website. It is expected that the presentations, followed by a question and answer session, will conclude at approximately 1pm ET. Any changes to these events and links to the live ...

 PRESS RELEASE

ICON releases its ICON Cares 2023 Report

DUBLIN--(BUSINESS WIRE)-- , (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its . This outlines how the company is delivering on its ESG, diversity, inclusion and belonging, and CSR goals, as delivered through its ICON Cares program. In recognition of its efforts, in 2023, ICON achieved gold medal status from EcoVadis, a leading provider of business sustainability ratings. It also achieved a B score on its CDP Climate Change response, up from a C in 2022. Most recently, ICON has been named by the Financial Times and Statista as one of ...

 PRESS RELEASE

ICON Announces Pricing of USD 2 Billion Notes

DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”). The Notes will be issued by ICON’s wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), and will be guaranteed on a senior secured basis by ICON and its exist...

 PRESS RELEASE

ICON Reports First Quarter 2024 Results

DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024. CEO, Dr. Steve Cutler commented, “ICON reported a strong start to the year in quarter one, with revenue growth of 6% year over year, and net bookings up 10% over quarter one 2023, resulting in a net book to bill ratio of 1.27 times. Adjusted earnings per share grew a robust 20% on a year over year basis, reflecting our efficient service delivery and strong cost control. Our performance is reflec...

 PRESS RELEASE

ICON Announces CFO Transition

DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO. “On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his st...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch